{"id":8750,"date":"2023-07-06T11:02:33","date_gmt":"2023-07-06T11:02:33","guid":{"rendered":"https:\/\/kraios.app\/news\/saglik\/2023\/07\/06\/ingiliz-hukumetiyle-biontech-yeni-kanser-asisi-denemeleri-icin-anlasma-imzaladi\/"},"modified":"2023-07-06T11:02:33","modified_gmt":"2023-07-06T11:02:33","slug":"ingiliz-hukumetiyle-biontech-yeni-kanser-asisi-denemeleri-icin-anlasma-imzaladi","status":"publish","type":"post","link":"https:\/\/kraios.app\/news\/saglik\/2023\/07\/06\/ingiliz-hukumetiyle-biontech-yeni-kanser-asisi-denemeleri-icin-anlasma-imzaladi\/","title":{"rendered":"\u0130ngiliz h\u00fck\u00fcmetiyle BionTech, yeni kanser a\u015f\u0131s\u0131 denemeleri i\u00e7in anla\u015fma imzalad\u0131"},"content":{"rendered":"<p><\/p>\n<div>\n<p>Ba\u015fbakanl\u0131k Ofisi 10 Numara&#8217;dan yap\u0131lan a\u00e7\u0131klamada, \u0130ngiliz h\u00fck\u00fcmetiyle BioNTech&#8217;in, 2030&#8217;a kadar 10 bin hasta \u00fczerinde yeni kanser a\u015f\u0131s\u0131 denemeleri i\u00e7in anla\u015fmaya imza att\u0131klar\u0131 bildirildi.<\/p>\n<p>A\u00e7\u0131klamada, ocakta imzalanan mutabakat zapt\u0131na dayanan bu ortakl\u0131\u011f\u0131n, kanser hastalar\u0131n\u0131n en son kanser denemelerine ve geli\u015ftirilmekte olan tedavilere daha kolay eri\u015fim sa\u011flayacaklar\u0131na i\u015faret edilerek, \u015fu ifadelere yer verildi: <\/p>\n<p>&#8220;H\u00fck\u00fcmet, daha fazla hastan\u0131n ki\u015fiselle\u015ftirilmi\u015f kanser tedavilerinden faydalanabilmesini sa\u011flamak amac\u0131yla Almanya merkezli BioNTech \u015firketiyle uzun vadeli ortakl\u0131k anla\u015fmas\u0131 imzalad\u0131. Bu anla\u015fma, ba\u011f\u0131\u015f\u0131kl\u0131k sistemini kanser h\u00fccrelerini tan\u0131mas\u0131 ve ortadan kald\u0131rmas\u0131 i\u00e7in uyararak hassas imm\u00fcnoterapilerin kullan\u0131m\u0131 yoluyla hastalar\u0131n tedavisine yard\u0131mc\u0131 olmay\u0131 ama\u00e7layan \u0130ngiltere merkezli klinik \u00e7al\u0131\u015fmalar\u0131 i\u00e7eriyor. Ama\u00e7, 2030&#8217;a kadar 10 bin kadar hastan\u0131n ki\u015fiselle\u015ftirilmi\u015f tedavilere eri\u015fimini sa\u011flamak.&#8221;<\/p>\n<p>A\u00e7\u0131klamada, ki\u015fiselle\u015ftirilmi\u015f kanser a\u015f\u0131s\u0131 denemelerine kat\u0131lma se\u00e7ene\u011fi sunulacak kanser hastalar\u0131ndan veri taban\u0131 olu\u015fturulaca\u011f\u0131 belirtilerek, \u00e7al\u0131\u015fman\u0131n, erken ve ge\u00e7 evre kanserli hastalara yard\u0131mc\u0131 olmay\u0131 ama\u00e7layaca\u011f\u0131, ba\u015far\u0131l\u0131 olmas\u0131 durumunda kanser a\u015f\u0131lar\u0131n\u0131n standart tedavinin par\u00e7as\u0131 haline gelebilece\u011fi vurguland\u0131. <\/p>\n<h3>BioNTech, \u0130ngiltere i\u00e7in yeni b\u00f6lgesel merkez kurmay\u0131 planl\u0131yor<\/h3>\n<p>BioNTech&#8217;in halihaz\u0131rda \u0130ngiltere&#8217;de klinik denemeler y\u00fcr\u00fctmeye ba\u015flad\u0131\u011f\u0131 kaydedilen a\u00e7\u0131klamada, hastalar\u0131n \u00e7o\u011funun 2026&#8217;dan itibaren veri taban\u0131na kaydedilmesinin beklendi\u011fi ve ba\u015fka denemelerin de ba\u015flat\u0131laca\u011f\u0131 bildirildi. <\/p>\n<p>A\u00e7\u0131klamada, BioNTech&#8217;in, bu ba\u011flamda ara\u015ft\u0131rman\u0131n ger\u00e7ekle\u015ftirilmesine yard\u0131mc\u0131 olmak amac\u0131yla Cambridge \u015fehrinde 70&#8217;ten fazla bilim insan\u0131n\u0131n \u00e7al\u0131\u015fabilece\u011fi yeni laboratuvarlar ve \u0130ngiltere i\u00e7in yeni b\u00f6lgesel merkez kurmay\u0131 planlad\u0131\u011f\u0131 kaydedildi. <\/p>\n<h3>&#8220;Kanserle m\u00fccadelede ileriye do\u011fru at\u0131lm\u0131\u015f b\u00fcy\u00fck ad\u0131m\u201d<\/h3>\n<p>A\u00e7\u0131klamada de\u011ferlendirmelerine yer verilen \u0130ngiltere Sa\u011fl\u0131k Bakan\u0131 Steve Barclay, s\u00f6z konusu ortakl\u0131\u011f\u0131n &#8220;kanserle m\u00fccadelede ileriye do\u011fru at\u0131lm\u0131\u015f b\u00fcy\u00fck ad\u0131m&#8221; oldu\u011funu ifade etti. <\/p>\n<p>BioNTech&#8217;in \u00dcst Y\u00f6neticisi (CEO) ve kurucu orta\u011f\u0131 U\u011fur \u015eahin de &#8220;\u00c7al\u0131\u015fman\u0131n ba\u015far\u0131l\u0131 olmas\u0131 halinde bu i\u015fbirli\u011fi sadece \u0130ngiltere&#8217;de de\u011fil, t\u00fcm d\u00fcnyada kanserli hastalar\u0131n sonu\u00e7lar\u0131n\u0131 iyile\u015ftirme potansiyeline sahip.&#8221; de\u011ferlendirmesinde bulundu. <\/p>\n<p>                            <span class=\"detay-foto-editor\">&#13;<br \/>\n                                <a href=\"https:\/\/www.aa.com.tr\/tr\/p\/abonelik-talep-formu\/1001\" target=\"_blank\" style=\"font-size:12px; color:#444; text-decoration:none;\" rel=\"noopener\">&#13;<br \/>\n                                    Anadolu Ajans\u0131 web sitesinde, AA Haber Ak\u0131\u015f Sistemi (HAS) \u00fczerinden abonelere sunulan haberler, \u00f6zetlenerek yay\u0131mlanmaktad\u0131r. <b style=\"color:#1897F7\">Abonelik i\u00e7in l\u00fctfen ileti\u015fime ge\u00e7iniz.<\/b>&#13;<br \/>\n                                <\/a>&#13;<br \/>\n                            <\/span>\n                        <\/div>\n<p><script>\n\t  window.fbAsyncInit = function() {\n\t\tFB.init({\n\t\t  appId: '1855843514662870',\n\t\t  status : true, \/\/ check login status\n\t\t  cookie : true, \/\/ enable cookies to allow the server to access the session\n\t\t  xfbml  : true  \/\/ parse XFBML\n\t\t});\n\t  };<\/p>\n<p>\t  (function() {\n\t\tvar e = document.createElement('script');\n\t\te.src=\"https:\/\/connect.facebook.net\/tr_TR\/all.js\";\n\t\te.async = true;\n\t\tdocument.getElementById('fb-root').appendChild(e);\n\t  }());\n    <\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ba\u015fbakanl\u0131k Ofisi 10 Numara&#8217;dan yap\u0131lan a\u00e7\u0131klamada, \u0130ngiliz h\u00fck\u00fcmetiyle BioNTech&#8217;in, 2030&#8217;a kadar 10 bin hasta \u00fczerinde yeni kanser a\u015f\u0131s\u0131 denemeleri i\u00e7in anla\u015fmaya imza att\u0131klar\u0131 bildirildi. A\u00e7\u0131klamada, ocakta imzalanan mutabakat zapt\u0131na dayanan bu ortakl\u0131\u011f\u0131n, kanser hastalar\u0131n\u0131n en son kanser denemelerine ve geli\u015ftirilmekte olan tedavilere daha kolay eri\u015fim sa\u011flayacaklar\u0131na i\u015faret edilerek, \u015fu ifadelere yer verildi: &#8220;H\u00fck\u00fcmet, daha fazla [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8751,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":[],"categories":[46],"tags":[],"_links":{"self":[{"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/posts\/8750"}],"collection":[{"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/comments?post=8750"}],"version-history":[{"count":0,"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/posts\/8750\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/media\/8751"}],"wp:attachment":[{"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/media?parent=8750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/categories?post=8750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/tags?post=8750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}